Develops a drug called CGT9486 that targets a specific genetic mutation — KIT D816V — that standard cancer drugs cannot hit without causing severe side effects.
At a glance
- Depends onMidstream position: 3 outgoing, 3 incoming connections
- Scale
Develops a drug called CGT9486 that targets a specific genetic mutation — KIT D816V — that standard cancer drugs cannot hit without causing severe side effects.
What this company is and how it runs — written from structure, not news.
Cogent Biosciences is built around a single molecular observation: the KIT D816V mutation locks the KIT kinase into a shape that standard KIT-blocking drugs cannot occupy at safe doses, because reaching that mutant pocket with a wild-type-targeting drug also hits wild-type KIT in gut tissue, causing toxicity that forces the dose below the level needed to work. CGT9486 is designed specifically around that mutant shape, so it can reach therapeutic concentrations in systemic mastocytosis patients without triggering that toxicity ceiling — and because the drug only works if patients actually carry the D816V mutation, every enrolled patient must first be confirmed positive through CLIA-certified laboratory testing, meaning the selectivity claim and the enrollment process are the same single gate. A competitor cannot simply copy this by spending more money; they would have to independently solve the same conformational targeting problem, run their own IND filings, and recruit from the same small, hard-to-find population of D816V carriers that Cogent's academic partners have already spent years locating. The whole structure rests on CGT9486 staying selective — if a clinical trial finds that the drug binds kinases beyond the D816V pocket at therapeutic doses, the toxicity problem returns, and with it collapses the enrollment criteria, the regulatory filings, and every licensing milestone that pharmaceutical partners have tied to that selectivity profile.
How does this company make money?
The company earns money by licensing CGT9486 and its other compounds to pharmaceutical partners who pay upfront fees for the rights to sell the drug in specific countries or for specific diseases. Partners also pay milestone payments when the drug clears defined clinical or regulatory hurdles. Once a drug is approved and on the market, the company collects royalties — a share of sales revenue — on compounds targeting KIT D816V mutations and CSF1R.
What makes this company hard to replace?
Oncologists who want to use a different KIT inhibitor instead would need that competing drug to complete its own separate clinical trials in systemic mastocytosis patients — the same small, hard-to-enroll population. Regulatory agencies require entirely new IND filings and independent safety records for any competing compound. Academic collaborators who have built testing protocols and biomarker assays around CSF1R pathway modulation cannot simply transfer that work to a drug that operates through a different biological mechanism.
What limits this company?
Only a fixed number of people in the world carry the KIT D816V mutation and have systemic mastocytosis. No amount of faster testing or more screening centers creates more eligible patients. Enrollment in every trial is therefore capped by biology, not by anything the company can change operationally.
What does this company depend on?
The company cannot operate without CLIA-certified laboratories to confirm KIT D816V mutation status in patients, FDA IND approvals to run clinical trials, contract manufacturing organizations capable of synthesizing selective kinase inhibitors, academic medical centers with systemic mastocytosis expertise to enroll and treat patients, and CSF1R expression biomarker assays to support its broader research programs.
Who depends on this company?
Systemic mastocytosis patients with the KIT D816V mutation would lose their only targeted treatment option if CGT9486 development fails. Oncologists at specialized cancer centers treating immunotherapy-resistant solid tumors would lose access to CSF1R inhibition options. Clinical research organizations running biomarker-driven trials depend on CGT9486 as a compound with a validated, specific target — if it disappeared, those trial designs would have no replacement molecule to work with.
How does this company scale?
Designing clinical protocols and synthesizing the molecular compound for additional diseases that share the same KIT D816V or CSF1R genetic targets can be done without starting over — the core chemistry and regulatory logic carry over. What cannot scale is the patient pool itself. The number of people who carry KIT D816V mutations or CSF1R-dependent tumors is fixed by biology, so no matter how efficiently the company operates, the total number of patients it can ever enroll stays permanently small.
What external forces can significantly affect this company?
FDA orphan drug designation policies control how long the company can have commercial exclusivity for systemic mastocytosis, a rare disease — changes to those policies directly affect the value of any approved drug. Medicare reimbursement decisions for precision oncology genetic tests determine whether patients can actually afford the diagnostic required to qualify for treatment. European Medicines Agency rules on how multi-regional rare cancer trials must be designed affect whether clinical data collected in the US can be used to win approval in Europe.
Where is this company structurally vulnerable?
If a clinical trial found that CGT9486 binds to kinases other than the D816V target at the doses needed to treat patients, the drug would cause the same toxicity that makes existing KIT inhibitors unusable at therapeutic doses. That single finding would invalidate the selectivity claim the entire company is built on — collapsing the enrollment criteria, the FDA trial protocols, and every payment milestone that pharmaceutical partners have tied to a confirmed selectivity profile.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign in2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock behaving?
Three observations have aligned in the up direction: the Ichimoku-cloud composite is firing on its up-side configuration, the trend-strength composite is in the upper portion of its mapped range, and the volume-weighted-returns sum over the 60-week lookback is net positive.
Current close sits in the upper portion of the 14-week high-low range; current close sits in the upper portion of its 20-week Bollinger Bands; RSI sits above its 20-week recent mean (Bollinger %B applied to RSI).
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
CompanyGraph